No of your stocks has realtime/relevant news articles that can be accessed.
Take a look into our News feed to read about recent price changes and analysis.
Sentiment statistics ?
Please use our Financial history templates to chart, read and compare all 10'Q filings in depth.
|Country Short Name
There is no dividend data to display. Refer our Dividend calendar for other accurate data.
Please sign up and become a member to view all risk profiles.
The 'Focus' Area is meant to be an One-Pager about all Important Insights, Risks and Opportunities to solely analyze a single corporate.
Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel vaccines and antibody medicines to treat unmet needs in cancer and infectious diseases. The company's product candidates include SCIB1, which is in phase II clinical trial for the treatment of metastatic melanoma; SCIB2 for the treatment of non-small cell lung cancer; and Modi-1 that is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers.